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Abstract
Background: This study elucidates exposure-response relationships between performance of repetitive tasks, grip strength
declines, and fibrogenic-related protein changes in muscles, and their link to inflammation. Specifically, we examined
forearm flexor digitorum muscles for changes in connective tissue growth factor (CTGF; a matrix protein associated with
fibrosis), collagen type I (Col1; a matrix component), and transforming growth factor beta 1 (TGFB1; an upstream modulator
of CTGF and collagen), in rats performing one of two repetitive tasks, with or without anti-inflammatory drugs.
Methodology/Results: To examine the roles of force versus repetition, rats performed either a high repetition negligible
force food retrieval task (HRNF), or a high repetition high force handle-pulling task (HRHF), for up to 9 weeks, with results
compared to trained only (TR-NF or TR-HF) and normal control rats. Grip strength declined with both tasks, with the greatest
declines in 9-week HRHF rats. Quantitative PCR (qPCR) analyses of HRNF muscles showed increased expression of Col1 in
weeks 3–9, and CTGF in weeks 6 and 9. Immunohistochemistry confirmed PCR results, and also showed greater increases of
CTGF and collagen matrix in 9-week HRHF rats than 9-week HRNF rats. ELISA, and immunohistochemistry revealed greater
increases of TGFB1 in TR-HF and 6-week HRHF, compared to 6-week HRNF rats. To examine the role of inflammation, results
from 6-week HRHF rats were compared to rats receiving ibuprofen or anti-TNF-a treatment in HRHF weeks 4–6. Both
treatments attenuated HRHF-induced increases in CTGF and fibrosis by 6 weeks of task performance. Ibuprofen attenuated
TGFB1 increases and grip strength declines, matching our prior results with anti-TNFa.
Conclusions/Significance: Performance of highly repetitive tasks was associated with force-dependent declines in grip
strength and increased fibrogenic-related proteins in flexor digitorum muscles. These changes were attenuated, at least
short-term, by anti-inflammatory treatments.
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Introduction
Work-related musculoskeletal disorders (WMSDs) occurring as
a result of repeated trauma continue to cause substantial numbers
of lost work days [1], disability and discomfort in US industry.
WMSDs include several diagnoses, including muscle disorders
[2,3]. However, the mechanisms leading to pathophysiological
tissue changes associated with WMSDs are incompletely un-
derstood. The 2010 National Manufacturing Agenda (NORA) of
the National Institute of Occupational Safety and Health
(NIOSH) cites the need for etiologic research in determining the
contribution of biomechanical mechanisms (e.g., repetitive motion)
towards the development of tissue injury and musculoskeletal
disorders, as well as strategies to reduce their severity [4].
Several animal models have been developed to study WMSDs
and have shown that repetitive hand activities induce motor
dysfunction [5,6,7,8,9,10,11,12,13,14,15]. When examining the
effects of performing either a high repetition or low repetition food
retrieval task (a negligible force task) in our rat model of voluntary
repetitive working, we observed exposure-dependent declines in
grip strength, with greater declines with the high repetition task
[6,11,16]. Performance of a high repetition, high force (HRHF)
handle-pulling task induced even greater declines in grip strength
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e38359[7,12,17]. However, mechanisms underlying these declines in
motor strength are still under investigation.
Some mechanisms examined to date in our model include task-
induced tissue injury, inflammation and fibrosis, each of which
may contribute to declines in grip strength by producing
discomfort or affecting biomechanical strength. Evidence of injury
includes focal myofiber fray as well as compression and degraded
myelin in the median nerve with performance of the high
repetition, negligible force (HRNF) task for 8 weeks [5]. Greater
signs of tissue injury were observed with performance of higher
force tasks, including moth-eaten muscle fibers [18]. These injuries
were paralleled by inflammatory responses, such as increased
tissue pro-inflammatory cytokines and macrophages [5,7,8,19,20].
These increases in inflammatory responses preceded fibrotic
responses in forelimb nerves, tendons and periosteum, including
connective tissue hyperplasia and increased connective tissue
growth factor (CTGF), periostin, periostin like factor (PLF), and
collagen type 1 [7,8,12,17,18,21]. However, we have yet to
examine muscles for similar fibrotic responses to these repetitive
tasks. If present, muscle fibrosis may well alter muscle bio-
mechanics in a manner that reduces grip strength [22,23,24].
Muscles have been shown to undergo repetitive strain-induced
fibrotic changes in forced lengthening models of repetitive motion.
Stauber and colleagues have shown that repeated muscle strains at
fast velocities (lengthening contractions stimulated electrically)
resulted in fibrotic myopathy with increased collagen content,
collagen cross-links and non-contractile tissues, while repeated
strains at low velocities did not [25,26,27,28]. Factors and
mechanisms of repetitive strain-induced fibrosis in tissues are still
under investigation, but appear to involve CTGF and transform-
ing growth factor beta-1 (TGFB1) [29,30,31,32,33]. Unfortunate-
ly, recovery from fibrotic changes is slow, even with complete
cessation of strain/activity for up to 3 months [27]. Blocking
tumor necrosis factor alpha (TNF-a) with antibodies has been used
to successfully reduce inflammation-induced kidney and liver
fibrosis, as well as collagen-induced arthritis, with subsequent
improvement in symptoms [34,35,36]. We have recently shown
that anti-rat TNF-a during the early stages of inflammation
attenuates repetitive task-induced increases of PLF, a matricellular
molecule that increases with tissue loading in musculoskeletal
tissues, and that TNF-a regulates PLF production in osteoblasts in
vitro [12]. Production of CTGF by fibroblasts, another matricel-
lular protein, is also regulated by TNF-a [37,38], although the
regulation of CTGF by TNF-a in muscles undergoing repeated
strain has yet to be investigated. The link between these
matricellular proteins and TNF-a gives insight into possible
mechanisms (i.e. inflammatory) that may drive fibrotic tissue
repair.
Our aims were to determine: a) if fibrogenic-related proteins
increase in skeletal muscles in response to prolonged repetitive
reaching, b) if their increases parallel declines in grip strength, c)
the extent to which increased force loads contribute to either
change, and d) if anti-inflammatory treatments attenuate these
responses. Since CTGF, collagen type 1, and TGFB1 increase
under conditions of muscle overload or injury and are linked to
tissue fibrosis [7,8,17,29,30,39,40,41], we hypothesized that these
proteins would increase with continued task performance and/or
force loads. Since these proteins are linked to tissue fibrosis, we
hypothesized that their increases would parallel grip strength
declines. We further hypothesized that, as with PLF [12,18,21],
that two other matrix regulatory proteins, TGFB1 and CTGF,
may also be linked to an early task-induced inflammatory
response. If so, then early administration of anti-inflammatory
drugs should decrease their production, the onset of muscle
fibrosis, and attenuate task-induced grip strength declines.
Methods
Animals
All experiments were approved by the Temple University
Institutional Animal Care and Use Committee (Temple University
IACUC) in compliance with NIH guidelines for the humane care
and use of laboratory animals. Rats were housed individually in
the central animal facility in transparent plastic cages in a 12 hour
light: 12 hour dark cycle with free access to water. Studies were
conducted on a total of 142, young adult (3.5–4 months of age at
onset of experiments), female, Sprague-Dawley rats.
Overview of training and task regimens
Seventeen rats served as age-matched normal controls (NC)
with free access to food, and did not undergo training or task
performance; 9 more NC rats received ibuprofen treatment
(NC+IBU). All but NC and NC+IBU rats were food restricted
(n=117) to within 5% of their naı ¨ve weights as described
previously [9,16]. These food restricted rats went through an
initial training period in which they learned to perform either
a high repetition negligible force, food retrieval task (TR-NF,
n=51) as described previously [5], or a high repetition high force,
handle-pulling task (TR-HF, n=56) as described previously
[7,18,21], for a food reward. The rats were trained for 10 min/
day, 5 days/week. This training period was either 10 days (TR-
NF) or 5–6 weeks (TR-HF) (learning to perform the high force task
took longer than the negligible force task).
Forty-one of the TR-NF rats went on to perform the high
repetition negligible force, food retrieval task (HRNF). These 41
rats performed the HRNF task for 2 hr/day, 3 days/week for 3
weeks (n=12), 6 weeks (n=11) or 9 weeks (n=18). Thirty-four of
the TR-HF rats went on to perform the high repetition high force,
handle-pulling task (HRHF). These 34 rats performed the HRHF
task for 2 hr/day, 3 days/week, for either 6 weeks (n=29), or 9
weeks (n=5). Subcohorts of the 6-week HRHF rats either went
untreated (6 HRHF, n=11), or were treated with anti-rat TNF-
a (6HRHF+anti-TNF, n=6) or ibuprofen (6HRHF+IBU, n=12)
in weeks 5 and 6 of HRHF task performance. The remaining TR-
NF (n=10) or TR-HF rats (n=32) were euthanized after the
training period, and served as trained-only controls. Subcohorts of
TR-HF rats, either went untreated (TR-HF, n=17), or received
anti-rat TNF-a (TR-HF+anti-TNF, n=6) or ibuprofen (TR-
HF+IBU, n=9) before euthanasia, as described further below.
All rats were weighed weekly and food adjusted accordingly. In
addition to food pellet rewards, all rats received Purina rat chow
daily. Trained-only rats received food pellets and rat chow that
matched allotments given to task rats. In accordance with the
recommendations of the Panel on Euthanasia of the American
Veterinary Medical Association, animals were euthanized using
sodium pentobarbital (120 mg/kg body weight) before tissue
collection.
Description of HRNF and HRHF task regimens
The HRNF and HRHF tasks have been described in detail
previously [5,7,18,21]. Briefly, the HRNF task was a forelimb food
pellet retrieval task in which rats reached and retrieved a food
pellet at a target reach rate of 4 reaches/min and ,5% maximum
pulling force (MPF; the 45 mg food pellet was estimated as ,5%
MPF) in customized operant behavioral apparati (Med Associates,
St Albans, VT), as described previously [5,6]. Force-dependent
changes were examined by having additional rats perform a high
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and 60% maximum pulling force. This task was a forelimb handle-
pulling task for a food reward that used customized operant
behavioral chambers as described previously [7,17,18].
Anti-inflammatory treatments
Ibuprofen: At the end of the 4th week of HRHF task
performance, 12 of the HRHF rats were administered liquid
ibuprofen (Children’s Motrin Grape Flavored, Johnson &
Johnson, New Brunswick, New Jersey) in drinking water daily
(45 mg/kg body weight), as described previously [42]. These
animals continued to perform the HRHF task regimen for two
more weeks while receiving the ibuprofen treatment
(6HRHF+IBU). Nine of the TR-HF rats (TR-HF+IBU) and 9
normal controls (NC+IBU) also received ibuprofen for 2 weeks.
The ibuprofen dose used was moderate, yet effective in reducing
HRHF-induced increases in tissue cyclooxygenase 2 and pro-
inflammatory cytokines in our rat model [42]. The amount of
medicated water consumed/day was tracked for each animal by
measuring the difference between the initial and final volume of
suspended solution daily. Blood was collected, centrifuged, and
serum levels of ibuprofen were tested using National Medical
Services (NMS, Willow Grove, PA). By these measures, it was
determined that all ibuprofen treated rats had between
48.866.3 mg/kg body weight of ibuprofen daily.
Anti-TNF-a: Another subcohort of HRHF rats were adminis-
tered an anti-rat TNF-a (CNTO 1081; generously provided by
Janssen R&D), as described previously [12]. Briefly, this drug was
injected intraperitoneally (i.p., 15 mg/kg body wt.) into HRHF
rats beginning mid-task week 4, at the end of task week 4, and at
the end of task week 5 (6HRHF+anti-TNF, n=6). Six of the TR-
HF rats received similar anti-TNFa treatment (TR-HF+anti-
TNF).
Determination of daily exposure and grip strength
Daily exposure (reaches/day) was obtained from: (a) 22
randomly chosen HRNF animals at the end of task weeks 1 and
3 (n=22 each), and weeks 6 and 9 (n=18 each) of HRNF task
performance [the number reduces across weeks due to euthanasia
for tissue analysis]; and (b) 14 randomly chosen untreated HRHF
animals at the end of task weeks 1 and 3 (n=14 each), and weeks 6
and 9 (n=7 each) of HRHF task performance. The mean daily
exposure, reaches/day, was determined by multiplying the reach
rate by the number of minutes per day that the rats participated in
the task.
Average grip strength was tested using previously described
methods [6] in: (a) 24 randomly chosen HRNF animals at the
naı ¨ve time point, at the end of training (week 0; TR), and in weeks
1–5, and weeks 6–9 (n=18 each) of HRNF task performance; and
from (b) 38 randomly chosen untreated HRHF animals at the
naı ¨ve time point, at the end of training (week 0; TR), and in weeks
1–4, weeks 5 and 6 (n=35), and weeks 7–9 (n=9) of HRHF task
performance. Average grip strength was also determined in
NC+IBU (n=9), TR-HF+IBU (n=9), and 6HRHF+IBU rats
(n=12). Grip strength has already been reported for anti-TNF-
a treated rats [12].
Quantitative Real-Time PCR (qPCR)
Fifteen animals were euthanized with an overdose of sodium
pentobarbital (120 mg/kg body weight) and forearm flexor
muscles (and associated proximal tendon slips) were collected
from Region A of the flexor digitorum mass as shown in Figure 1A
from NC, TR-NF, and 3-, 6- and 9-week HRNF rats (n=3/
group). Each muscle belly was divided into two longitudinal parts;
half was used for RNA extraction and half for protein extraction.
The half for RNA extraction was put into RNAlater RNA
Stabilization Reagent (QIAGEN, Valencia, CA) for 2 hours at
room temperature, and then stored at 280uC. Total RNA was
isolated using TRIzol reagent (Invitrogen, Carlsbad, CA). The
concentration of each RNA sample was determined using
a spectrophotometer; the integrity was monitored on 1%
formaldehyde denatured gels. After confirming RNA integrity,
cDNA was prepared from mRNA extracts from the above tissue
samples (n=3/group), using a High Capacity cDNA Reverse
Transcription kit (Applied Biosystems
TM, Foster City, CA). PCR
primer sets for the following were used: Collagen type I alpha1
(Col1; Cat# PP42922APPR42922A), CTGF (Cat# PPR46426A)
and GAPDH (Cat# PPR51520A) (SABiosciences, Frederick,
MD). qPCR was then performed in duplicate for 20 ml reactions,
using the SYBR Green PCR Master Mix method (Applied
Biosystems, Foster City, CA) on an ABI 7500 Fast Real-Time
PCR system (Applied Biosystems
TM). PCR cycles consisted of an
initial cycle of 50uC for 2 min and the second cycle of 95uC for
10 min, followed by a two-step program of 95uC for 15 sec and
60uC for 1 min for 40 cycles. Using GAPDH as the internal
control, relative gene expression among samples was calculated by
comparison of Ct (threshold cycle) values. A dissociation curve was
checked for each qPCR run to confirm specific amplification of
target RNA.
Synthesis of CTGF riboprobe and in situ hybridization
A CTGF cDNA fragment of approximately 700 bp of the 3
9
end of the rat CTGF cDNA was cloned into PCR-Script vector
(Stratagene, LaJolla, CA) flanked by the T3 and T7 promoters to
generate CTGF sense and CTGF anti-sense riboprobes. Concen-
tration of the sense and anti-sense riboprobe was determined using
an in situ hybridization labeling kit (Roche Diagnostic). For in situ
hybridization of CTGF in flexor digitorum muscles, animals were
euthanized and flexor digitorum muscles and tendons from NC
and 9-week HRNF rats were harvested (n=3/group), fixed in 4%
paraformaldehyde in phosphate buffered saline (PBS) at 4uC,
dehydrated, embedded in paraffin, sectioned (5 mm sections), and
placed on charged slides (Super Frost Plus, ThermoFisher
Scientific, Pittsburgh, PA). In situ hybridization was then carried
out as described previously [43].
Immunohistochemical analyses
Animals received an overdose of sodium pentobarbital
(120 mg/kg body weight) before being perfused transcardially
with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4):
NC (n=6); TR-NF (n=5); TR-HF (n=10), TR-HF+IBU (n=4),
TR-HF+anti-TNF (n=3); 3-week HRNF (n=7); 6-week HRNF
(n=5); 9-week HRNF (n=10); 6-week HRHF (n=6); 9-week
HRHF (n=4); 6HRHF+IBU (n=7); and 6HRHF+anti-TNF
(n=3). Tissues were collected and postfixed ‘‘en bloc’’ by
immersion overnight. A proximal portion of the muscle mass
was then removed with a scalpel for cross-sectional sectioning (as
shown with vertical dashed lines in Fig. 1A), while the remaining
flexor digitorum muscles and tendons were separated en bloc as
a flexor mass from the bones for longitudinal sectioning (included
both Regions A and B as shown in Fig. 1A). All tissues were
cryoprotected in 30% sucrose in PBS before frozen-sectioning
using a cryostat into 15 mm longitudinal or cross sectional slices.
Sections were then placed onto charged slides (Fisher, Super Frost
Plus) and allowed to dry overnight before storage at 280uC.
Sections on slides were treated with 3% H2O2 in methanol to
block for endogenous peroxidase for 30 min, washed in PBS, and
then blocked with 10% goat serum in PBS for 20 min at room
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bilized with 0.05% pepsin in 0.01N HCL, prior to blocking with
10% goat serum in PBS for 20 min, and prior to primary antibody
incubation. Sections were then incubated overnight at room
temperature with primary antibody diluted in 10% goat serum in
PBS. Primary antibodies were as follows: anti-CTGF (Cat# sc-
14939, 1:400 dilution, Santa Cruz Biotechnology, Santa Cruz,
CA), anti-collagen type I (Cat# C2456, 1:500 dilution, Sigma-
Aldrich, St. Louis, MO), and TGFB1 (Cat# MAB240, 1:300
dilution, R&D Systems). On the 2
nd day, after washing, sections
Figure 1. Forelimb tissues examined, daily exposure, and grip strength declines. (A) Flexor digitorum muscles were collected from region
A of the flexor digitorum muscles, a region containing primarily muscle but also proximal tendon slips (short arrows). The vertical dashed lines
indicate the region of muscle cut into cross-section for histological analysis. The remaining part of region A and region B were sectioned together
longitudinally. Lumbricals are located in region B (long arrows in the palm). Region A was used for PCR, ELISA and western blot analyses in separate
animals than those for histology. (B) Daily exposure (mean reaches/day) decreased similarly in both groups with continued task performance, and
dropped below the target of 480 reaches/day (indicated by dotted line) in each by week 9, although significantly lower only in week 9 HRNF rats
compared to their week 1 level. **p,0.01 compared to same group week 1. (C) Average grip strength decreased in both groups with continued task
performance, with the greatest declines in HRHF week 9. *p,0.05, **p,0.01, ***p,0.001, compared to naı ¨ve;
#p,0.05,
##p,0.01,
###p,0.001
compared to HRHF week 0 (end of training period (TR) for TR-HF rats);
&p,0.05 compared to 9-week HRNF rats. (D) Grip strength declines in the
preferred reach limb of trained (TR-HF) and 6-week HRHF rats were attenuated after two weeks of ibuprofen treatment in trained rats (TR-HF+IBU)
and HRHF rats (6HRHF+IBU). ***p,0.001 compared to NC;
&p,0.05 compared to untreated 6-week HRHF rats.
doi:10.1371/journal.pone.0038359.g001
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gated to HRP (Jackson Immunoresearch Laboratories, West
Grove, PA; each were diluted 1:100 in PBS, and incubated
2 hours at room temperature before washing in PBS) and
visualized using DAB with or without cobalt (black versus brown,
respectively; Fast DAB, Sigma), or with appropriate secondary
antibody conjugated to Cy2 (green fluorescent tag) or Cy3 (red
fluorescent tag) (Jackson Immunoresearch Laboratories). DAB-
treated sections were counterstained lightly with eosin. Slides were
either dehydrated and coverslipped with DPX mounting medium
for bright field microscopy (for HRP-DAB) or washed with PBS
and coverslipped with 80% glycerol in PBS for epifluorescence
microscopy. Negative control staining was performed by omitting
either the primary antibody or the secondary antibody. Specificity
of the TGFB1 antibody was determined via the use of a TGFB1
blocking (Santa Cruz Biotechnology Cat# sc-146 P). Western blot
analysis, using methods described previously [12], was used to
show that proteins of the correct molecular weight were
immunodetected with the CTGF and collagen type I antibodies
in skeletal muscle (as shown in the results section and figures).
Quantification of the immunohistochemical findings was per-
formed using an image analysis program (Bioquant, Nashville,
TN) and methods, as described previously [17,19]. Other subsets
underwent Masson’s trichrome staining as described [44].
ELISA of musculoskeletal tissues
Animals were euthanized with an overdose of sodium pento-
barbital (120 mg/kg body weight) before tissue collection from
Region A of the flexor digitorum mass (Fig. 1A) from NC (n=8),
NC+IBU (n=5), TR-NF (n=5), TR-HF (n=5), TR-HF+IBU
(n=5), TR-HF+anti-TNF (n=3), 6-week HRNF (n=6), 6-week
HRHF (n=5), 6HRHF+IBU (n=5), and 6HRHF+anti-TNF
(n=3). As described above, the muscles were divided into half
longitudinally. The half for protein analysis was snap frozen and
stored at 280uC until homogenization, and then prepared for
protein analysis, as described previously [6,12]. Total protein was
determined using BCA-200 protein assays (Bicinchoninic Acid,
Pierce, Rockford, IL). For ELISA, tissue lysates (50 microliter
aliquots) were analyzed using a commercially available ELISA kit
for TGFB1 (Cat# PA1-9574, Pierce), according to the manu-
facturers’ protocol. Each sample was run in duplicate. ELISA
assay data (pg protein) were normalized to mg total protein.
Statistical Analysis
Repeated measures, mixed model, two-way ANOVAs were
used to analyze grip strength, with the factors group (HRNF and
HRHF) and week (naı ¨ve, 0–9). Two-way ANOVAs, with the
factors group and week, were used to analyze daily exposure and
CTGF. Univariate ANOVA was used to analyze quantitative
PCR and TGFB1 ELISA for differences in task weeks versus
controls. Univariate ANOVA was also used to examine for drug
effects on CTGF, TGFB1 and grip strength, to examine for any
significant changes between controls, task and treatment groups.
Statistical analyses were performed using Prism 5 (GraphPad
Software, La Jolla, CA). All post hoc analyses were carried out
using the Bonferroni test for multiple comparisons as indicated;
adjusted p values are reported. An adjusted p value of ,0.05 was
considered significant for all analyses. Data are presented as the
mean 6 standard error of the mean (SEM).
Results
Daily exposure to repetitive tasks
Daily exposure showed significant declines towards the target of
480 reaches/day with continued task performance (Fig. 1B; 2-way
ANOVA: week, p=0.003; group, p=0.01), suggestive of skill
acquisition, decreased performance abilities, or a combination of
the two. Specifically, in both groups, rats tended to overreach
initially. By week 9, reaches/day declined below the target in
HRNF rats, compared to HRNF week 1 (p,0.01), suggesting skill
acquisition because it declined toward their target reach rate. In
HRHF rats, reaches/day declined by week 9, but not significantly,
compared to HRHF week 1, suggesting that rats in this higher
force group are self-regulating their reach rate due to discomfort
(as shown in Fedorczyk et al, 2010). Nevertheless, since reaches/
day were similar statistically between the groups, force level rather
than reaches/day was a key difference between the two groups
(,5% maximum pulling force in HRNF compared to 60% in
HRHF tasks rats).
Grip Strength declined with continued performance of
both tasks, more with HRHF
Grip strength showed significant declines with continued task
performance in both groups (Fig. 1C; 2-way ANOVA: week,
p,0.001; group, p=0.03). Specifically, TR-NF rats did not have
declines in grip strength compared to naı ¨ve rats (indicated as
0(TR) in Fig. 1C), but TR-HF rats showed significant declines by
the end of their training period, compared to naı ¨ve rats (p,0.01).
Each group showed declines in grip strength with continued task
performance, compared to naı ¨ve rats (See Fig. 1C for p values).
Compared across groups, 9-week HRHF rats had the greatest grip
strength declines, compared to 9-week HRNF rats (p,0.05;
Fig. 1C). Thus, both force level and chronicity of exposure
contributed to declines in grip strength.
Grip strength declines were attenuated by ibuprofen
treatment
Since we have shown that administration of the anti-rat TNF-
a during the early stages of inflammation attenuates HRHF task-
induced declines in grip strength [12], we sought to determine
here if ibuprofen treatment had a similar effect. Grip strength
showed significant declines in each group with continued task
performance (Fig. 1D; 1-way ANOVA: p,0.001). Specifically,
grip strength declines observed in TR-HF rats, compared to NC
(p,0.01), were attenuated in TR-HF+IBU rats. Likewise, grip
strength declines observed in 6-week HRHF rats, compared to NC
rats (p,0.001), were attenuated in 6-week HRHF+IBU rats
(p,0.05 compared to 6-week HRHF). The 6-week HRHF+IBU
rats had grip strengths similar to NC and NC+IBU rats (Fig. 1D).
Exposure-dependent increases in CTGF and collagen
type 1; CTGF increases more with HRHF
We initially explored if there were changes in expression of
CTGF and collagen type I in rats performing the HRNF task, and
found that each increased with continued HRNF task perfor-
mance (Fig. 2A–D). Using qPCR analyses, we observed a signif-
icant upregulation of CTGF expression in 6- and 9-week HRNF,
compared to TR-NF rats (Fig. 2A, p,0.01 each) and a significant
upregulation of Col1 expression in 3-, 6- and 9-week HRNF,
compared to TR-NF rats (Fig. 2B; p,0.05, p,0.001, and p,0.01,
respectively). In situ hybridization was used to confirm the CTGF
gene expression and showed increased CTGF in 9-week HRNF
(Fig. 2D; note small dark stained cells on periphery of myofibers
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(Fig. 2C).
Immuohistochemistry was used to determine if CTGF protein
levels also increased, as well as the cellular and spatial location of
the CTGF protein. HRNF flexor digitorum muscles showed only
a small but non-significant increase in CTGF immunostaining in
9-week HRNF, compared to NC rats (Fig. 3B versus Fig. 3A;
Fig. 3E). Therefore, we extended our study to include a higher
force demand task (i.e. the HRHF task), and found increased
CTGF in large mast-like cells near blood vessels (arrowheads in
Fig. 3C), and in many small cells at edges of myofibers (Fig. 3D).
Quantification of the immunostaining showed increased CTGF
immunoreactivity in 9-week HRHF muscles, compared to NC and
compared to 9-week HRNF rats (p,0.001 each; Fig. 3E).
Figure 3F shows that the anti-CTGF antibody detected a 38 kDa
Figure 2. Examination of expression levels of connective tissue
growth factor (CTGF) and collagen 1 (Col1) with HRNF task
using quantitative PCR (qPCR). RNA was extracted from region A of
the flexor digitorum muscles of normal controls (NC), trained-only rats
(TR-NF), and HRNF rats that had performed the task for 3, 6 or 9 weeks.
(A,B) Quantitative real-time PCR (qPCR) showing CTGF and Col1 mRNA
expression levels, relative to GAPDH. qPCR data represents average of
n=3/gp.
#p,0.05,
##p,0.01,
###p,0.001, compared to TR-NF. (C) NC
muscle (M) cut in cross section showed no expression of CTGF mRNA
using in situ hybridization. (D) 9-week HRNF muscle showed increased
CTGF mRNA using in situ hybridization in small cells around myofibers
(M) and in surrounding connective tissue (ct). Similar in situ
hybridization results were replicated in n=3/gp. Scale bars=50 mm.
doi:10.1371/journal.pone.0038359.g002
Figure 3. Connective tissue growth factor immunostaining
increased more in HRHF muscles than in HRNF. Cross-sections
(panels A,B,D), and longitudinal sections (panel C) from region A of
flexor digitorum muscles (M) are shown. (A) NC muscle showing only
low levels of CTGF immunostaining. (B) 9-week HRNF muscle showing
a small increase in CTGF-immunostained cells at peripheral edges of
myofibers (arrows). (C) 9-week HRHF muscle showing increased CTGF in
larger mast-like cells (arrowheads) near a blood vessel (bv). (D) 9-week
HRHF muscle also contained smaller CTGF-immunostained cells
(arrows) at the periphery of myofibers. Inset shows higher power of
the CTGF-immunostained cells at edges of myofibers. (E) Quantification
of CTGF immunostaining in flexor digitorum muscles. (F) A lane from
a representative Western blot showing that the CTGF antibody used for
the immunohistochemistry detects a band at 38 kDa in the flexor
digitorum muscles, the expected molecular weight of CTGF. The whitish
band below the 38 kDa band indicates the site of GAPDH. The gel was
first stained with anti-GAPDH and then stripped prior to staining with
anti-CTGF. ***p,0.001 and
###p,0.001, compared to NC and TR-HF,
respectively (n=3–10/gp). Scale bars=50 mm.
doi:10.1371/journal.pone.0038359.g003
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of flexor digitorum skeletal muscle from a HRHF animal.
qPCR findings for collagen type I were confirmed qualitatively
using immunohistochemistry (Fig. 4). There was no collagen type I
immunostaining in or around NC myofibers (Fig. 4A). However,
collagen type I immunostaining was visible around myofiber slips
at sites where muscles attached to tendons in 9-week HRNF rats
(Fig. 4B and inset). Collagen type I immunostaining was even
more pronounced in flexor digitorum muscle of 9-week HRHF
rats in the endomyseum (Fig. 4C), small cells around myofibers,
and within some individual myofibers (Fig. 4D). Figure 4E shows
that the anti-collagen 1 type antibody detected bands that matched
the expected molecular weights of collagen type 1 precursors and
mature collagen type I, in western blots of flexor digitorum skeletal
muscles from HRHF rats, matching previously published molec-
ular weights for collagen type 1 [45,46].
TGFB1 increases are greater with higher force training
and task performance
Since TGFB1 has been shown to be an upstream modulator of
CTGF and collagen production in myofibroblasts [32,41], and has
been implicated in muscle fibrosis [41], we looked for its increase
in the flexor digitorum muscles (Fig. 5). Immunohistochemistry
showed little to no TGFB1 immunostaining in NC rats (Fig. 5A).
In contrast, a clear increase of small cells immunopositive for
TGFB1 were observed at the periphery of myofibers and in the
endomyseum between myofibers in 6-week HRHF rats (Fig. 5B).
ELISA was used for quantification of TGFB1 protein levels and
revealed significant increases of TGFB1 in TR-HF and 6-week
HRHF flexor digitorum muscles, compared to NC rats (p,0.05
each; Fig. 5E). A two-week treatment of HRHF rats with
ibuprofen treatment reduced TGFB1 immunoexpression, com-
pared to untreated 6-week HRHF rats (p,0.05; compare Fig. 5C
to 5B; Fig. 5F). A two week treatment of HRHF rats with anti-
TNF-a treatment also reduced TGFB1 immunoexpression,
although not significantly (compare Fig. 5D to 5B; Fig. 5F).
TGFB1 levels in 6HRHF+antiTNF and 6HRHF+IBU were not
significantly different from NC levels (Fig. 5F).
Anti-inflammatory drugs decrease CTGF and matrix in
HRHF rats
Since production of CTGF by fibroblasts is also regulated by
TNF-a [37,38], we examined the effects of both anti-TNF-a and
ibuprofen on CTGF and matrix deposition in the flexor digitorum
muscles. Both treatments decreased the initial HRHF-training and
HRHF-task induced increases in CTGF and collagen matrix
(Fig. 6). TR-HF rats had small increases in CTGF immunoreac-
tivity (Fig. 6A), but little staining was seen in TR-HF-anti-TNF
rats (Fig. 6B), although neither change was significantly different
from NC (Fig. 6G). The amount of CTGF in TR-HF+IBU was
also not significantly difference from that in NC (Fig. 6G). In
contrast, CTGF immunoreactivity was greater in untreated 6-
week HRHF muscles, compared to NC rats (Fig. 6C,F,G;
p,0.01). However, CTGF staining was significantly lower in 6-
week HRHF rats treated with either anti-TNF-a or ibuprofen
(6HRHF+anti-TNF and 6HRHF+IBU rats), compared to un-
treated 6-week HRHF rats (Fig. 6D–G; p,0.01 each). Lumbrical
muscles of the palm also showed decreased collagen matrix
staining in 6HRHF+anti-TNF rats compared to 6-week HRHF
rats (compare Fig. 6I to 6H). Similar decreases in collagen matrix
staining were observed lumbricals of 6HRHF+IBU rats (data not
shown).
Discussion
Our aims were to determine: a) if fibrogenic-related proteins
increase in skeletal muscles in response to prolonged repetitive
reaching, b) if their increases parallel declines in grip strength, c)
the extent to which increased force loads contribute to either
change, and d) if anti-inflammatory treatments attenuate these
responses. We found that CTGF and TGFbeta1 increased in
flexor digitorum muscles, particularly in cells in the interstitial
matrices (endomyseum), in an exposure-dependent manner with
greater increases with continued task performance and with higher
force. These changes were associated temporally with increased
Figure 4. Collagen immunostaining increases in flexor digi-
torum muscles with HRNF and HRHF tasks. Cross-sections (panels
A,B,D), and longitudinal sections (panel C) from region A of flexor
digitorum muscle (M) are shown. (A) NC muscle (M) showing no
immunostaining for collagen type 1 in or around individual myofibers.
(B) 9-week HRNF muscle showing increased collagen type I staining
around a few myofibers. Arrows indicate collagen immunoreactive
staining extending around individual myofibers. Inset shown higher
power photo of area in panel B indicated with an asterisk. (C,D) 9-week
HRHF muscle showing increased collagen type I staining in the
endomyseum (panel C), and in small cells at the edges of some
myofibers (arrows; panel D), as well as within some myofibers (panel
D).The T in panel C indicates a small tendon slip within the muscle mass
region. Similar results were observed in n=3/gp. (E) Lanes from
a representative Western blot of flexor digitorum muscles from HRHF
rats probed with the collagent y p e1a n t i b o d yu s e df o rt h e
immunohistochemistry. Lane 1 shows the standards; Lane 2 shows
bands at the expected molecular weights of procollagen type I
(approximately 140 kDa; [45,46]) and mature collagen (75 Kda here;
known to be between 70 and 90 kDa; [45]); Lane 3 from a different
muscle sample showing mainly detection of a band at the molecular
weight of mature collagen. Scale bars=50 mm.
doi:10.1371/journal.pone.0038359.g004
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Both anti-inflammatory treatments lead to decreased CTGF and
collagen matrix deposition in HRHF rats, despite continued task
performance. In contrast, TGFB1 decreased significantly with
ibuprofen treatment, but not with anti-TNF-a. Task-induced grip
strength declines were also attenuated by ibuprofen treatment,
again, despite continued task performance, matching our past
results showing improved grip strength with anti-TNF-a treatment
[12]. Since both anti-inflammatory drugs attenuated CTGF and
collagen production, as well as grip strength declines, it is possible
that inflammation-induced matrix changes contribute to declines
in grip strength.
Daily exposure (mean reaches/day) was fairly similar in both
the food retrieval task and handle-pulling task (the HRNF and
Figure 5. TGFB1 increases in TR-HF and 6-week HRHF rats and is attenuated by ibuprofen. (A) NC muscle cut in cross-section showing no
TGFB1 immunoreactive cells. (B) 6-week HRHF muscle showing TGFB1-immunostained cells at edges of myofibers (arrows). (C) Muscle from a 6-week
HRHF rat treated with ibuprofen (6-wk HRHF+IBU) showing fewer TGFB1-immunostained cells than in panel B. (D) Muscle from a 6-week HRHF rat
treated with anti-TNF-a (6-wk HRHF+anti-TNF) showing reduced TGFB1 immunostaining. (E) ELISA results for TGFB1 in muscles from NC, 6-week
HRNF, TR-HF, and 6-week HRHF rats; n=3–8/gp. (F) Quantification of percent area of muscle with TGFB1 immunostaining. *p,0.05 compared to NC;
&p,0.05 compared to untreated 6-week HRHF; n=4–10/gp. Scale bars=50 mm.
doi:10.1371/journal.pone.0038359.g005
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levels initially in both task groups, and then declined in each group
to target levels with continued task production. Thus, one key
difference between the tasks was force level (,5% maximum
pulling force in the HRNF task versus 60% in the HRHF task).
The progressive declines in grip strength with both tasks
supports an exposure dependent influence on this motor variable.
Figure 6. Increased CTGF and collagen staining decreases after anti-inflammatory drug treatments. CTGF immunohistochemistry
(panels A–F) and Masson’s trichrome staining (panels G,H) increased in flexor digitorum muscles (M) and lumbricals in TR-HF and 6-week HRHF task
rats, and decrease with anti-inflammatory drugs. Panels A–F show CTGF immunostaining (red) of flexor digitorum muscles from: (A) TR-HF, (B) TR-HF
treated with anti-TNF-a, (C) untreated 6-week HRHF (showing CTGF-immunostained cells at edges of myofibers), (D) 6-week HRHF treated with anti-
TNF-a (inset shows small CTGF-immunostained cells in endomyseum), (E) 6-week HRHF treated with ibuprofen, and (F) untreated 6-week HRHF
(showing increased CTGF-immunostained cells in endomyseum (ct)). (G) Quantification of percent area with CTGF immunostaining. **p,0.01
compared to NC;
## p,0.01 compared to TR-HF;
&&p,0.01 compared to untreated 6-week HRHF; n=4–12/gp. (F) Lumbricals from Region B stained
with Masson’s Trichrome showing: (H) increased blue stained collagen matrix in an untreated 6-week HRHF rat, and (I) decreased blue staining in a 6-
week HRHF treated with anti-TNF-a. Scale bars=50 mm.
doi:10.1371/journal.pone.0038359.g006
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while the improvement after ibuprofen treatment supports
a contribution from inflammatory mechanisms. Since there were
greater increases in matrix protein production and interstitial
matrices in HRHF than HRNF rats, we postulate that task-
induced matrix changes also contributed to the declines in grip
strength. This matches results by Cutlip et al showing increased
cellular interstitial responses in skeletal muscles after chronic
administration of stretch-shortening cycles, and decreased func-
tional performance (decreased isometric and peak eccentric
forces), even in the absence of myofiber necrosis [22]. On the
other hand, increased muscle inflammatory cytokines, including
TNF-a, also correlates with declines in grip strength [6,16,47]. We
have reported that both systemic ibuprofen and anti-TNF-
a treatment attenuates HRHF task-induced increases of in-
flammatory cytokines in musculoskeletal tissues [12,42], and that
the anti-TNF-a treatment improves grip strength [12]. Further-
more, treatment of subjects with subcutaneous TNF-a receptor
before unaccustomed exercise improves muscle strength [48], as
does ibuprofen [49,50]. Thus, we are unable to separate the effects
of increased inflammation from increased matrix deposition on
grip strength in our model. We can only postulate that our findings
combined with those by other groups [22,48,49,50] indicate that
both muscle fibrosis and inflammation contribute to our observed
repetitive task induced grip strength declines. The extent to which
the combined effects of these two processes are additive, or worse,
is unknown but raises the possibility that individuals prone to
fibrotic matrix deposition may be more susceptible to functional
loss with repetitive task exposure than those who experience
a predominantly inflammatory response.
Several studies have examined the effects of cyclical loading and
repeated muscle strains on extracellular matrix content, including
collagen [7,8,17,22,24,25,26,27,28,29]. There is also data con-
cerning the influence of physical exercise, mechanical loading
andcyclical loading on CTGF and TGFB1 production in
musculoskeletal tissues. We have reported increased CTGF as
well as collagen production in involved nerves and tendons of rats
performing HRNF and HRHF tasks for 9–12 weeks [7,8,17].
Cyclical loading of tendons also results in increased CTGF [30].
Acute exercise does not alter TGFB1 mRNA levels in skeletal
muscles [51]. In contrast, prolonged treadmill running of 60 min/
day for 6 weeks leads to increased TGFB1 mRNA but not
increased TGFB1 protein levels [51], perhaps because their
training protocol was geared more towards endurance training
rather than overload or overuse. TGFB1, CTGF and collagen
type 1 increase in skeletal muscle after 4 days of isometric and
eccentric training, although not after concentric training [33]. This
suggests that muscle is sensitive to differences in contraction type
or force production, although the latter study was not designed to
answer that question specifically. A strong link between mechan-
ical loading and TGFB1 mRNA and protein levels in tendons and
isolated fibroblasts has been established [32,39,52]. Our results
now establish a similar link between increased force loads and
increased TGFB1, CTGF and collagen type I in skeletal muscles
during repetitive task performance using an in vivo model.
Our observed fibrotic muscle responses paralleled increases in
CTGF and TGFB1. Several groups have shown that CTGF is
a secreted matricellular protein associated with tissue repair and
fibrosis [41,52,53] (also reviewed by [40,53]. TGFB1 is also an
established and potent stimulator of connective tissue formation in
skeletal muscle healing after injury, particularly at sites of
mechanical stress [32,33]. CTGF’s mediation of collagen pro-
duction and fibrosis is regulated at least partially by TGFB1
[32,39,53,54]. This explains our findings that TGFB1 increases
significantly in TR-HF rat muscles prior to increases of CTGF in
HRHF muscles. We also observed that ibuprofen treatment
reduced TGFB1 production, despite continued muscle loading, as
well as CTGF and collagen matrix. The reduction in TGFB1 by
ibuprofen likely contributed to the reduced CTGF; and reduced
CTGF contributed to the reduced collage n production and
deposition in the muscles.
Mechanical loading of tissues also increases production of
fibroblast growth factor (FGF), platelet derived growth factor
(PDGF), and vascular endothelial growth factor (VEGF) in muscle
and tendon fibroblasts [30,55,56]. For example, mechanical
loading increases FGF release in vitro from skeletal muscle cells;
associated muscle cell growth is inhibited after administration of
an antibody that neutralizes FGF activity [57]. FGF2 (basic FGF),
and to a lesser extent FGF1 (acidic FGF), are potent stimulators of
fibroblast proliferation, collagen formation, and fibrogenic tissues
changes [58]. FGF subtypes (FGF-2 and FGF-6) combined with
TGFB contribute to collagen production, albeit this has been
shown only in chondrocytes to date [59]. These findings indicate
that we should examine VEGF, PDGF and FGF subtypes in future
studies in our model.
CTGF production also appears to be regulated by TNF-
a [37,38], matching our observation of decreased CTGF and
collagen matrix after anti-TNF-a treatment. A direct role for
CTGF in tissue fibrosis is controversial, since studies show that
a cooperative interaction between CTGF and TGFB is needed for
overt tissue fibrosis [32,39,53]. On the other hand, Sonnylal and
colleagues have reported that overexpression of CTGF by
fibroblasts is directly linked to tissue fibrosis in vivo [41]. We
have shown that anti-TNF-a treatment-down regulates a related
matricellular protein, PLF (periostin like factor) [12]. However, in
that study, we found that anti-TNF-a treatment did not reduce
CTGF in HRHF rat muscles using western blot analysis. Perhaps
homogenization and then Western blot analysis of a large muscle
mass is not sensitive enough to detect the early CTGF changes
observed here using immunohistochemistry. Concerning the
ibuprofen induced decreases in CTGF, we reported recently that
ibuprofen treatment reduces task-induced increases of several
inflammatory cytokines, including TNF-a, in skeletal tissues in our
model [42]. Based on these results combined, we postulate that
ibuprofen-induced reductions in tissue inflammatory cytokines and
TGFB1 lead to the observed reductions in CTGF in the ibuprofen
treated rats.
With regard to which anti-inflammatory drug might be more
efficacious for patients with WMSDs, both therapies used in this
study seems to decrease the detrimental effect of muscle fibrosis at
the expense of CTGF production. Therefore, since Ibuprofen
treatment is the least expensive method, it might be the most
appropriate therapy. However, its use should be limited to short-
term treatments. Ibuprofen medication has been shown in a few
studies to suppress protein synthesis after eccentric exercise. It may
also inhibit skeletal muscle hypertrophy and adaptation with
training [49,60,61,62], although a more recent study shows no
effect of ibuprofen on muscle hypertrophy [50]. The usefulness of
long-term anti-TNF-a treatments for WMSDS has yet to be
explored, although it has been shown to reduce inflammation and
scarring in experimental glomerulonephritis and hepatic fibrosis
[35,36]. It is clear though from this study, that despite a continued
increase of TGFB1 in HRHF muscles, that CTGF can be targeted
to reduce prolonged loading induced skeletal muscle fibrosis.
Perhaps even more specific drugs can be developed that are
effective, inexpensive and easy to administer to lower CTGF in
muscle and therefore fibrosis.
High Force Tasks Induce Increased Muscle Fibrosis
PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e38359Our results are similar to those by Lapoint in 2002, in an animal
model of exercise-induced muscle damage [63]. They found that
administration of an anti-inflammatory drug (diclofenac sodium)
during the acute inflammation phase (during the first 3 days) after
unaccustomed eccentric contractions was effective at restoring
muscle force. However, delayed administration of diclofenac
sodium to a time point when the inflammatory response was
declining had no effect on muscle force. In this study of cumulative
repetitive loading across many weeks, the timing of anti-
inflammatory drug administration to HRHF rats was at the onset
of the inflammatory process. We have previously shown that the
macrophage and inflammatory cytokine response begins around
week 3 and continues through week 12 in musculotendinous
tissues of HRHF rats [12,17]. We timed the drug administration in
this study to be during this early inflammatory phase in the hopes
of preventing inflammation-induced catabolic responses. We have
yet to investigate the effectiveness of drugs at later time points, but
hypothesize that anti-inflammatory drugs will not be effective post
inflammation. It is clear from this study that despite a continued
increase of TGF-beta 1 in HRHF muscles, CTGF can be targeted
more specifically to reduce prolonged loading-induced skeletal
muscle fibrosis. There is recent evidence in the literature
demonstrating that it is possible to specifically target CTGF to
abrogate CTGF-dependent skeletal muscle dystrophy/fibrosis and
tumor growth [64,65]. Levels of CTGF have been shown to be
markedly elevated in various injured tissues that develop fibrosis
including the skin, kidney, liver and lung [66,67,68,69,70]. More
recently, CTGF over-expression has been implicated in the
pathophysiology of dystrophic skeletal muscles where it is believed
to contribute to the deterioration of skeletal muscles and their
function in addition to mediating the ensuing fibrosis of the
damaged muscle tissue [65]. Clinical trials are currently underway
using a fully human IgG1k monoclonal antibody that recognizes
domain 2 of human and rodent CTGF (this monoclonal is called
FG-3019 and was developed by Fibrogen, Inc., South San
Francisco, CA) as a novel therapy to treat patients with Pancreatic
cancer, idiopathic pulmonary fibrosis, and liver fibrosis due to
chronic hepatitis B infection [71]. This antibody has also been
used to treat CTGF-expressing tumors in mice, where it abrogated
CTGF-dependent pancreatic tumor growth and lymph node
metastasis without any toxic side effects in mice [64]. FG-3019 has
also been used as a therapy in a mouse model of Duchenne
muscular dystrophy, where it reversed the fibrosis of muscular
tissue and even allowed return of skeletal muscle function (personal
communication, Dr. Enrique Brandan). These studies support the
concept of using drugs that specifically target CTGF as a treatment
to prevent reduced skeletal muscle function and the ensuing
fibrosis that occurs as a consequence of overuse in WMSDs.
It is also possible that genetic predisposition to fibrosis may, in
part, explain why some individuals are more prone to functional
losses with exposure to repetitive tasks. Models that explore the
interactions between such genetic factors and environmental
exposures may provide additional insight into and guidance
toward appropriate and individualized treatment approaches.
In conclusion, these data suggest that continuous repetitive
loading of skeletal muscles, particularly with high force, stimulated
the production of fibrogenic proteins (CTGF and TGFB1). This
increase was accompanied by increased collagen synthesis and
matrix deposition as well as reduced grip strength. Early treatment
with anti-inflammatory drugs (anti-TNF-a and ibuprofen) suc-
cessfully attenuated production of CTGF and collagen matrix
deposition. Ibuprofen treatment also attenuated TGFB1 pro-
duction. Lastly, grip strength improved with both anti-inflamma-
tory treatments. However, since this is a short study, with only
short-term anti-inflammatory treatments, similar anti-fibrotic
results may not be sustained with longer task regimens.
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